Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

62 Results

Guidelines and Advice

Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment

Status: Current

Sep 2022

Guidelines and Advice

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Status: Current
Version: 2

Updated

Sep 2025

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Aug 2023

Guidelines and Advice

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Status: Current
ID: C50-CIDAP-1

Mar 2024

Guidelines and Advice

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

Status: Current
ID: GL 9-11

Oct 2024

Guidelines and Advice

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Status: Current
ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

Systemic Treatment Emergency Preparedness Guidance Document

Status: Current

Updated

Aug 2025

Guidelines and Advice

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

Status: Current
ID: GL END 4-19

Updated

Nov 2025

Guidelines and Advice

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

Status: Current
ID: GL 1-22-A
Version: 2

Jul 2022

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Aug 2022

Guidelines and Advice

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Status: Current
ID: GL 5-3ORG
Version: 2

Apr 2019

Pages